Jaguar Health (NASDAQ:JAGX) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Jaguar Health (NASDAQ:JAGX) in a report issued on Friday. The brokerage issued a sell rating on the biotechnology company’s stock.

Jaguar Health Trading Down 7.1 %

JAGX opened at $5.00 on Friday. Jaguar Health has a 12 month low of $4.90 and a 12 month high of $540.00. The company has a current ratio of 1.84, a quick ratio of 1.36 and a debt-to-equity ratio of 1.65. The business’s 50-day moving average price is $16.51 and its 200-day moving average price is $23.26.

Institutional Investors Weigh In On Jaguar Health

A hedge fund recently bought a new stake in Jaguar Health stock. Virtu Financial LLC bought a new stake in Jaguar Health, Inc. (NASDAQ:JAGX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 25,591 shares of the biotechnology company’s stock, valued at approximately $35,000. Virtu Financial LLC owned 0.22% of Jaguar Health as of its most recent SEC filing. 12.04% of the stock is currently owned by institutional investors.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.